After Cantor Fitzgerald and Wedbush gave Aimmune Therapeutics (NASDAQ: AIMT) a Buy rating last month, the company received another Buy, this time from Credit Suisse. Analyst Vamil Divan maintained a Buy rating on Aimmune Therapeutics yesterday and set a price target of $40. The company’s shares closed yesterday at $30.29.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -2.0% and a 45.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Johnson & Johnson, and Merck & Company.
Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $57.83, which is a 90.9% upside from current levels. In a report issued on November 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $62 price target.
The company has a one-year high of $42 and a one-year low of $24.56. Currently, Aimmune Therapeutics has an average volume of 463.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
Read More on AIMT: